ºÚÁÏÍø

ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
ºÚÁÏÍø

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ ºÚÁÏÍø Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

ºÚÁÏÍø Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Citations : 4334

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Share This Page

Ampakine Farampator (CX691) improves cognitive impairment and hippocampus BDNF levels in a rat model of AÃ?²1-42-induced Alzheimer′s disease

9th International Conference on Alzheimers Disease & Dementia

Ayat Kaeidi

Rafsanjan University of Medical Sciences, Iran

Posters & Accepted Abstracts: J Alzheimers Dis Parkinsonism

DOI:

Abstract
An emerging body of data suggests that dysfunction of the glutamatergic system and AMPA receptors has been implicated in Alzheimerâ��s disease (AD). Because AMPA receptor plays a critical role in the regulation of hippocampus synaptic plasticity, the positive modulation of this receptors may rescue learning and memory deficits in AD. In the present study, by using the Morris water maze paradigm, we explored the pro-cognitive effect of Farampator, a specific positive allosteric modulator of the AMPA-type glutamate receptors in rat model of AD produced by injection of amyloid-beta1-42 (A�²1-42) in to the hippocampus. Furthermore, we investigated the effects of Farampator on brain derived neurotrophic factor (BDNF) protein expression in the hippocampus tissue. Results show that intrahippocampal injection of A�²1-42 caused learning and memory deficits in rats subjected to the Morris water maze and decreased BDNF expression in the hippocampus. Also we found that treatment with farampator for 10 days (0.3 mg/kg, twice a day) improved the performance of Alzheimeric rats in Morris water navigation task with increased level of BDNF protein. Altogether, our data suggest that Farampator ameliorate A�²1-42-induced learning deficits, at least part, via up-regulation of BDNF protein in the hippocampus. The results of this investigation may shed light on a possible therapeutic approach to treating and control the progression of AD.
Biography

Ayat Kaeidi has started his PhD at the age of 32 years from Rafsanjan University of Medical Sciences. He has published more than 12 papers in reputed journals.
 

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top